Anthrogen operates an AI-research lab focused on building the network for biologics discovery and development. The company utilizes its protein generation engine, Odyssey, which reasons across modalities to design molecular machines. This computational approach is grounded in massively parallelized experimentation to validate designs for human and planetary health applications.
Funding
$4.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
BPGWVFounders
Product
Problem
The production of sustainable polymers and fuels relies on affordable and scalable feedstock solutions, but current methods often struggle to achieve both economic viability and carbon neutrality. Traditional manufacturing processes can be environmentally damaging and fail to address the urgent need for carbon-negative alternatives.
Solution
Anthrogen utilizes CRISPR-engineered bacteria and enzymatic cascade technology to manufacture carbon-negative chemicals from atmospheric carbon dioxide. By engineering fast-photosynthesizing organisms, Anthrogen has created a unified platform for next-generation protein foundry and enzymatic cascade technology. This platform enables the production of sustainable polymers, alkane mixes for jet fuel, and alternatively branched starches for industrial applications. The company's approach offers a climate-friendly and scalable solution for feedstock manufacturing.
Target Audience
Anthrogen's primary customers are companies in the sustainable polymer, alternative fuel, and industrial chemical sectors seeking carbon-negative feedstock solutions.
Features
- CRISPR-engineered bacteria for enhanced carbon dioxide conversion
- Enzymatic cascade technology for efficient chemical synthesis
- Production of carbon-negative polymers, fuels, and industrial chemicals
- Unified platform for protein engineering and enzymatic processing
- Scalable manufacturing process for cost-effective production